Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine

Vaccine

Volumn 16, Issue 19, 1998, Pages 1842-1849

  Fusco, Peter C ^a   Michon, Francis ^a   Laude Sharp, Maryline ^a   Minetti, Conceição A S A ^a   Huang, Chun Hsien ^a   Heron, Iver ^a   Blake, M S ^a  

^a North American Vaccine Inc   (United States)

Author keywords

Conjugate; Haemophilus influenzae; Porin

Indexed keywords

CARRIER PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; PORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; IMMUNE RESPONSE; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS VACCINES; IMMUNOGLOBULIN G; MICE; MICE, INBRED STRAINS; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; PORINS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0032210729     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00174-1     Document Type: Conference Paper

References (26)

1. 1 1997 Red Book: Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL, 1997.
2. 2 Eskola, J., Olander, R.M., Hovi, T., Litmanen, L., Peltola, S. and Kayhty, H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae Type b conjugate vaccine. Lancet 1996, 348, 1688-1692.
3. 3 Fusco, P.C., Michon, F., Tai, J.Y. and Blake, M.S. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. Journal of Infectious Diseases 1997, 175, 364-372.
4. 4 Lowell, G.H., Smith, L.F., Seid, R.C. and Zollinger, W.D. Peptides bound to proteosomes via hydrophobia feet become highly immunogenic without adjuvant. Journal of Experimental Medicine 1988, 167, 658-663.
5. 5 Lowell, G.H., Ballou, W.R., Smith, L.F., Wirtz, R.A., Zollinger, W.D. and Hockmeyer, W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 1988, 240, 800-802.
6. 6 Wetzler, L.M., Blake, M.S., Barry, K. and Gotschlich, E.C. Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from rmp deletion mutants. Journal of Infectious Diseases 1992, 166, 551-555.
7. 7 Livingston, P.O. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Annals of the New York Academy of Science 1993, 690, 204-213.
8. 8 Livingston, P.O., Calves, M.J., Helling, F., Zollinger, W.D., Blake, M.S. and Lowell, G.H. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993, 11, 1199-1204.
9. 9 Qi, H.L., Tai, J.Y. and Blake, M.S. Expression of large amounts of neisserial porin proteins in Escherichia coli and refolding of the proteins into native trimers. Infection and Immunity 1994, 62, 2432-2439.
10. 10 Minetti, C.A.S.A., Tai, J.Y., Blake, M.S., Pullen, J.K., Liang, S.M. and Remeta, D.P. Structural and functional characterization of a recombinant PorB class 2 protein from Neisseria meningitidis. Conformational stability and porin activity. Journal of Biological Chemistry 1997, 272, 10710-10720.
11. 11 Mach, H., Middaugh, C.R. and Lewis, R.V. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Analytical Biochemistry 1992, 200, 74-80.
12. 12 Jennings, H.J., Roy, R. and Gamian, A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. Journal of Immunology 1986, 137, 1708-1713.
13. 13 Reuter, G. and Schauer, R., Determination of sialic acids. In Methods in Enzymology Vol. 230 Techniques in Glycobiology, eds W.J. Lennarz and G.W. Hart. Academic Press, New York, 1994, pp. 168-199.
14. 14 Jennings, H.J., Gamian, A., Michon, F. and Ashton, F.E. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. Journal of Immunology 1989, 142, 3585-3591.
15. 15 Eskola, J. Analysis of Haemophilus influenzae type B conjugate and diphtheria-tetanus-pertussis combination vaccines. Journal of Infectious Diseases 1996, 174, (Suppl 3), S302-S305.
16. 16 Schneerson, R. Immunogenicity and safety of mixed DTP/IPV/ Hib vaccines. Lancet 1997, 349, 881-882.
17. 17 Schneerson, R., Barrera, O., Sutton, A. and Robbins, J.B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. Journal of Experimental Medicine 1980, 152, 361-376.
18. 18 Polotsky, V.Y., Robbins, J.B., Bryla, D. and Schneerson, R. Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid. Infection and Immunity 1994, 62, 210-214.
19. 19 Gupta, R.K., Szu, S.C., Finkelstein, R.A. and Robbins, J.B. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae 01 serotype Inaba bound to cholera toxin. Infection and Immunity 1992, 60, 3201-3208.
20. 20 Siber, G.R., Anderson, R., Habafy, M. and Gupta, R.K. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 1995, 13, 525-531.
21. 21 Lowell, G.H., Proteosomes, hydrophobic anchors, iscoms, and liposomes for improved presentation of peptides and protein vaccines. In New Generation Vaccines, eds G.C. Woodrow and M.M. Levine. Marcel Dekker, Inc., New York, 1990, pp. 141-160.
22. 22 Wetzler, L.M. and Ho, Y., Neisserial porins induce upregulation of B cell costimulatory ligand, B7-2: possible mechanisms behind their adjuvant activity. In Vaccines '95, ed. Anon. Cold Spring Harbor Press, New York, 1995, pp. 237-242.
23. 23 Wetzler, L.M. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Annals of the New York Academy of Science 1994, 730, 367-370.
24. 24 Melancon, J., Murgita, R.A. and DeVoe, I.W. Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens. Infection and Immunity 1983, 42, 471-479.
25. 25 Sparkes, B.G. Immunomodulating activity of meningococcal antigens. Canadian Journal of Microbiology 1983, 29, 1611-1618.
26. 26 Sparkes, B.G. Dual effect of meningococcal antigens on a T cell dependent immune response. Canadian Journal of Microbiology 1983, 29, 1619-1625.